Mirae Asset Global Investments’s Viking Therapeutics VKTX Stock Holding History

Mirae Asset Global Investments’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,284	Closed	-$528K	–	1669
2024 Q4	$528K	Buy	+13,284	New	+$757K	﹤0.01%	938
2024 Q2	–	Sell	-32,942	Closed	-$2.7M	–	2518
2024 Q1	$2.7M	Sell	32,942 -104,921	-76%	-$4.67M	0.01%	1060
2023 Q4	$2.6M	Buy	137,863 +294	+0.2%	+$3.85K	0.01%	1141
2023 Q3	$1.57M	Buy	137,569 +18,811	+16%	+$269K	﹤0.01%	1285
2023 Q2	$1.89M	Buy	118,758 +98,287	+480%	+$2.06M	﹤0.01%	1240
2023 Q1	$341K	Buy	+20,471	New	+$211K	﹤0.01%	2103

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mirae Asset Global Investments's VKTX Position: Q1 2025 in Review

Mirae Asset Global Investments sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 13,284 shares — an estimated $528K sold.

Mirae Asset Global Investments first reported a position in VKTX in Q1 2023 and held it in 6 quarters. The position peaked at $2.7M in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

Mirae Asset Global Investments reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
Mirae Asset Global Investments sold 13,284 Viking Therapeutics shares in Q1 2025, an estimated $528K.
Mirae Asset Global Investments first reported a position in Viking Therapeutics in Q1 2023 and held it in 6 quarters.
Mirae Asset Global Investments's Viking Therapeutics position peaked at $2.7M in Q1 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Mirae Asset Global Investments's 13F filing for Q1 2025, filed 24 Apr 2025.